The North America insulin drugs and delivery devices market is projected to grow from USD 10.48 billion in 2025 to around USD 20.23 billion by 2035, expanding at a CAGR of 6.80%. Growth is driven by the rising prevalence of diabetes, increasing adoption of advanced insulin delivery systems, and ongoing innovations in diabetes care technologies.

North America Insulin Drugs and Delivery Devices Market Statical Scope

The North America market for insulin drugs and delivery devices is growing significantly. Key growth factors for this market in North America include the availability of advanced research and development facilities, the presence of major players, and supportive regulatory frameworks. Government organizations are launching initiatives and providing funding to control diabetes, as well as for research and the development of innovative delivery devices.

North America Insulin Drugs and Delivery Devices Market Share, By Diabetes Type, 2025 (%)

• Type 2 Diabetes- Type 2 Diabetes holds a share of 62%. This growth is supported by high prevalence linked to obesity, sedentary lifestyles, and growing demand for long-term insulin therapy. Demand for personalized medicine is also boosting the segment growth.
• Type 1 Diabetes- Type 1 Diabetes leads the segment, with a share of 28%. This growth is driven by lifelong insulin dependency and growing early diagnosis rates. Patients need a continuous supply of insulin in type 1 diabetes, and therefore boost the demand for insulin drugs and delivery devices.
• Gestational Diabetes- Gestational Diabetes accounts for a share of 6%, driven by growing maternal age and improved prenatal screening. Understanding the complications and the higher risk of type 2 diabetes for both mother and child drives demand for effective management strategies.

North America Insulin Drugs and Delivery Devices Market Share, By End User, 2025 (%)

• Hospitals- Hospitals lead the segment, with a 34% share, driven by high inpatient demand and structured insulin administration. Hospitals play a vital role in educating patients and their families on insulin injection techniques, device use and self-management.
• Homecare Settings- Homecare Settings account for a share of 32%. This is mainly due to rising self-administration and patient preference for at-home care. Home care options can lower hospital readmissions and reduce healthcare costs, becoming a popular choice among patients.
• Diabetes Clinics/Centers- Diabetes Clinics/Centers hold a significant share, with a share of 26%. This growth is driven by specialized diabetes management and monitoring services. Diabetes clinics are the primary setting for educating and training patients on advanced delivery systems.

North America Insulin Drugs and Delivery Devices Market Share, By Distribution Channel, 2025 (%)

• Retail Pharmacies- Retail Pharmacies dominate the segment, with a share of 38%. This dominance is driven by easy accessibility, wide availability within local communities and increasing patient preference for regular insulin purchases.
• Hospital Pharmacies- Hospital Pharmacies hold a share of 30%. This is attributed to inpatient care and clinical dispensing. They offer advanced insulin devices like pens, pumps, and pens-filled pens, alongside insulin drugs.
• Direct Tender/Bulk Procurement- Direct Tender/Bulk Procurement accounts for a notable share of 15%. This growth is mainly driven by institutional purchasing, healthcare system contracts and expanding national health services.
• Online Sales- Online Sales hold a smaller share, with a share of 12%. This is supported by rising digital prescription fulfillment. Furthermore, online platforms extend the reach of insulin products to a large patient population.

Top Companies in the North America Insulin Drugs and Delivery Devices Market

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Medtronic plc
• Insulet Corporation
• Tandem Diabetes Care, Inc.
• Ypsomed AG
• Biocon Biologics Ltd.
• Wockhardt Ltd.
• Becton
• Dickinson and Company (BD)
• F. Hoffmann-La Roche Ltd
• Abbott Laboratories (for CGM-integrated devices)
• Jiangsu Wanbang Biopharmaceuticals
• Julphar Gulf Pharmaceutical Industries
• MannKind Corporation
• Roche Diabetes Care
• Valeritas, Inc.
• Cellnovo Group SA
• Nipro Corporation
• Gerresheimer AG

Segments Covered in the Report

By Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Others (e.g., steroid-induced, MODY)

By End User

• Hospitals
• Diabetes Clinics/Centers
• Homecare Settings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales
• Direct Tender/Bulk Procurement
• Others